Navigation Links
Prodrug in Medical News

FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults

Basingstoke, U.K. and Philadelphia, PA April 23, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY,), the global specialty biopharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE (lisdexamfetamine dimesylate), for the treatment o...

Medinox Announces Clinical Results of Naproxen Prodrug

SAN DIEGO, May 26 /PRNewswire/ -- Medinox, Inc. (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. (Waltham, MA) announced the results of a double-blind, randomized, active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, in subjects 45 to 70 years of age. LT-NS001...

BioMarin Announces Second Quarter 2009 Financial Results

... expand and protect the market, and improve the ability of healthcare providers and patients to better manage their disease. These programs include a prodrug form of BH4, as well as a state-of-the-art handheld device to measure blood Phe levels in PKU patients. Human studies for each of these are planned f...

New strategy in tumor treatment

...le normal tissues are well protected." They go on to state, "Among the drugs used to kill the tumor cells, two -- thioguanine and fluorouracil (or its prodrug Xeloda) - are already in clinical use. In general, the dose of these drugs is limited by toxic side effects. However, with our strategy, greatly inc...

BELLUS Health Inc. Announces $12 Million Rights Offering To Common Shareholders

...velopment for the treatment of Type II diabetes and certain features of metabolic syndrome, approximately $2 million for the development of NRM8499, a prodrug of tramiprosate for the treatment of Alzheimer's disease, and approximately $1.4 million for other research and development (R&D) projects. The re...

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

...artners for development and commercialization of ProLindac in additional territories. About ProLindac(TM): ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's u...

Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal

...ugh would provide a $2 million upfront payment to Valeant and pay mid-single digit royalties on net sales of taribavirin in Japan. Taribavirin, a prodrug of ribavirin, is in Phase II development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. "This agreement w...

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

...NTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug di...

Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence

...igned for use with the study drug (hexaminolevulinate), which is instilled into a patient's bladder prior to the therapeutic procedure. This acts as a prodrug that initiates a series of biochemical reactions in malignant cells which result in significant, preferential accumulation of photoactive porphryins....

Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting

...Pharmaceuticals (NYSE: VRX ) today announced that results from the week-60 analysis for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon, was presented today at the E...
Prodrug in Medical Technology

TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel

LA JOLLA, Calif., June 4 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced it has initiated a clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of its lead product candidate, tezampanel. The randomized, double-blind, placebo-c...

Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache

- Company Plans to Initiate Phase IIa Study of NGX426 in Acute Migraine in First Half of 2008 - LA JOLLA, Calif., Dec. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today reported pharmacokinetic data obtained in a Phase I maximum tolerated dose cli...

Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, today announced that they presented data from a Phase I clinical trial of their anti-cancer compound, DTS-201, at th...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...RA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA((R)), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug di...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...tners for development and commercialization of ProLindac in additional territories. About ProLindac(TM): ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's u...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

..., today announced that it has successfully completed a three-day proof-of-concept study of IDX184. Idenix is developing IDX184, a novel liver-targeted prodrug of 2'-methyl guanosine nucleotide, for the treatment of HCV. This double-blind, placebo-controlled, monotherapy, dose-escalation study eval...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

...rsion of VYVANSE to its active form was not affected when coadministered with Prilosec OTC 40 mg, which relates to the characteristics of VYVANSE as a prodrug stimulant." As a prodrug, VYVANSE is converted to its active form by the body's natural metabolism. This conversion takes place minimally in the...

Telik Announces Presentation at ASCO Annual Meeting

...NTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug di...

Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

... pharmacokinetics of TR-701, a novel oxazolidinone prodrug antibiotic, in healthy adult subjects; KA. Munoz, ...ending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. ...ending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. ...

Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference

...s School of Medicine, presented the findings. Researchers have paired vorinostat, known by its pharmaceutical name Zolinza(R), with Aminoflavone prodrug (also known as AFP464) and found that AFP464 and vorinostat work together to inhibit the growth of triple-negative breast cancer cells. "Triple-negati...
Prodrug in Biological Technology

TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel

LA JOLLA, Calif., Oct. 20 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced it initiated dosing of the first cohort of subjects in a Phase I multiple dose clinical trial of NGX426, the oral prodrug of its most advanced product candidate, tezampanel. The trial is d...

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults

Within the First Eight Months Since its Introduction in the United States, VYVANSE has Achieved Over One Million Prescriptions In a Clinical Study With Adults, VYVANSE was Shown to Significantly Improve the Symptoms of ADHD (Inattention, Hyperactivity and Impulsivity)(1) BASINGSTOKE, ...

Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug

WALTHAM, Mass., Aug. 18 /PRNewswire/ -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today the successful completion of its Phase 1b randomized controlled multi-dose saf...

NeurogesX Reports Second Quarter 2009 Results

...t partners to advance its acetaminophen and opioid prodrug product candidates. NGX-9674 and NGX...ter versus acetaminophen. NGX-1576, a novel prodrug coupling acetaminophen to a liver protectant, has ...advanced molecule synthesized in NeurogesX' opioid prodrug platform, has been evaluated in proof of concept ...

Telik Announces Second Quarter 2009 Financial Results

...A(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug di...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.

...ompany focused on the discovery and development of prodrug cancer therapies. A prodrug is an inactive precursor of a drug that is convert...developed a novel approach to chemotherapy using a prodrug to deliver a potent, cell-killing agent to tumor s...

Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study

... -- Valeant Pharmaceuticals International (NYSE: VRX ) today reported final results for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. The study in treatment naiv...

NeurogesX Reports First Quarter 2009 Results

...velopment of Qutenza, NGX-1998 and our preclinical prodrug development programs. As a result of our conservat...t partners to advance its acetaminophen and opioid prodrug product candidates. NGX-9674 a...r versus acetaminophen. NGX-1576, a novel prodrug coupling acetaminophen to a liver protectant, has ...

Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting

...treatment with AFP-464 is the right direction in the clinical development of this difficult to treat disease." About AFP-464 AFP-464, a Lysol prodrug of aminoflavone (AF), undergoes rapid conversion to AF by nonspecific plasma esterases. It has shown a unique pattern of growth inhibitory activity i...

Telik Reports Preclinical Results at AACR Annual Meeting

...A(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug di...
Other Tags
(Date:3/2/2015)... ProvidaStaff has announced today that ... division to EDU Healthcare to reflect better ... systems and students nationwide. , “ProvidaStaff has always been ... the country,” said Angela M. Lewis, President of ProvidaStaff. ... and the introduction of EDU Healthcare better aligns our ...
(Date:3/1/2015)... 2015 To help healthcare ... their practices compliantly and profitably, MDreferralPRO and ... The interoperability between a strategic referral ... practice management system is necessary for a ... A referral management and development solution relies ...
(Date:3/1/2015)... Metamora, Michigan (PRWEB) March 01, 2015 ... approved to treat Overactive Bladder (OAB) symptoms, such as a ... adults when another type of medication (anticholinergic) does not work ... different treatment option that takes another approach to targeting the ... BOTOX® works on the nerves and bladder muscle, blocking the ...
(Date:3/1/2015)... March 01, 2015 A federal ... http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to trial in ... a witness to provide testimony regarding the role ... of the Profemur device, Bernstein Liebhard LLP comments. ... Court, Northern District of Iowa on February 25th, ...
(Date:3/1/2015)... ERISAPros is pleased to announce the ... professional staff of its Compliance Department. , Evelyn King, ... University-Mortiz College of Law. Prior to joining ERISAPros, Evelyn ... Fortune 500 companies as well as several privately held ... experiences range from benefit plan design, vendor management, administrative ...
Breaking Medicine News(10 mins):Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
Other Contents